• 1.

    Paik JM, et al. Sodium-glucose cotransporter 2 inhibitors and nephrolithiasis risk in patients with type 2 diabetes. JAMA Intern Med 2024; 184:265274. doi: 10.1001/jamainternmed.2023.7660

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 2.

    Anan G, et al. Inhibition of sodium-glucose cotransporter 2 suppresses renal stone formation. Pharmacol Res 2022; 186:106524. doi: 10.1016/j.phrs.2022.106524

  • 3.

    Kristensen KB, et al. Sodium–glucose cotransporter 2 inhibitors and risk of nephrolithiasis. Diabetologia 2021; 64:15631571. doi: 10.1007/s00125-021-05424-4

  • 4.

    Cosentino C, et al. Nephrolithiasis and sodium-glucose co-transporter-2 (SGLT-2) inhibitors: A meta-analysis of randomized controlled trials. Diabetes Res Clin Pract 2019; 155:107808. doi: 10.1016/j.diabres.2019.107808

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 5.

    Cianciolo G, et al. Mineral and electrolyte disorders with SGLT2i therapy. JBMR Plus 2019; 3:e10242. doi: 10.1002/jbm4.10242

  • 6.

    Harmacek D, et al. Empagliflozin changes urine supersaturation by decreasing pH and increasing citrate. J Am Soc Nephrol 2022; 33:10731075. doi: 10.1681/ASN.2021111515

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 7.

    Bletsa E, et al. Effect of dapagliflozin on urine metabolome in patients with type 2 diabetes. J Clin Endocrinol Metab 2021; 106:12691283. doi: 10.1210/clinem/dgab086

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 8.

    Pak CY, et al. Spontaneous precipitation of brushite in urine: Evidence that brushite is the nidus of renal stones originating as calcium phosphate. Proc Natl Acad Sci USA 1971; 68:14561460. doi: 10.1073/pnas.68.7.1456

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 9.

    Maalouf NM, et al. Association of urinary pH with body weight in nephrolithiasis. Kidney Int 2004; 65:14221425. doi: 10.1111/j.1523-1755.2004.00522.x

  • 10.

    Onishi A, et al. A role for tubular Na+/H+ exchanger NHE3 in the natriuretic effect of the SGLT2 inhibitor empagliflozin. Am J Physiol Renal Physiol 2020; 319:F712F728. doi: 10.1152/ajprenal.00264.2020

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 11.

    Wiederkehr MR, Moe OW. Uric acid nephrolithiasis: A systemic metabolic disorder. Clin Rev Bone Miner Metab 2011; 9:207217. doi: 10.1007/s12018-011-9106-6

SGLT2i: The New Wonder Drugs for Kidney Stone Prevention?

Amy A. Yau Amy A. Yau, MD, FASN, is an assistant professor of medicine in the Division of Nephrology at The Ohio State University Wexner Medical Center, Columbus. David S. Goldfarb, MD, FASN, is a professor of medicine and physiology in the Nephrology Division at New York University Langone Medical Center and New York University Grossman School of Medicine and is with the Veterans Affairs New York Harbor Healthcare System, New York.

Search for other papers by Amy A. Yau in
Current site
Google Scholar
PubMed
Close
and
David S. Goldfarb Amy A. Yau, MD, FASN, is an assistant professor of medicine in the Division of Nephrology at The Ohio State University Wexner Medical Center, Columbus. David S. Goldfarb, MD, FASN, is a professor of medicine and physiology in the Nephrology Division at New York University Langone Medical Center and New York University Grossman School of Medicine and is with the Veterans Affairs New York Harbor Healthcare System, New York.

Search for other papers by David S. Goldfarb in
Current site
Google Scholar
PubMed
Close
Restricted access
Save